Novavax, Inc. (NASDAQ:NVAX) Receives Consensus Recommendation of “Hold” from Analysts

Novavax, Inc. (NASDAQ:NVAX) has been assigned an average recommendation of “Hold” from the seven analysts that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $18.00.

Several analysts recently commented on NVAX shares. BTIG Research began coverage on shares of Novavax in a report on Friday, February 28th. They set a “buy” rating and a $19.00 target price for the company. HC Wainwright restated a “buy” rating and set a $19.00 price objective on shares of Novavax in a report on Tuesday, December 10th. Finally, TD Cowen upgraded Novavax to a “hold” rating in a research note on Thursday, February 27th.

Institutional Investors Weigh In On Novavax

Several institutional investors have recently made changes to their positions in NVAX. GF Fund Management CO. LTD. acquired a new stake in shares of Novavax during the 4th quarter worth $27,000. Spire Wealth Management acquired a new stake in shares of Novavax during the 4th quarter worth approximately $29,000. New Age Alpha Advisors LLC bought a new position in Novavax in the fourth quarter valued at approximately $35,000. KBC Group NV raised its position in Novavax by 97.0% during the fourth quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company’s stock valued at $64,000 after purchasing an additional 3,917 shares in the last quarter. Finally, TigerOak Management L.L.C. acquired a new stake in shares of Novavax in the 4th quarter valued at $86,000. 53.04% of the stock is currently owned by institutional investors.

Novavax Stock Down 0.3 %

Shares of NASDAQ NVAX opened at $5.98 on Thursday. The business’s 50 day moving average price is $7.98 and its two-hundred day moving average price is $9.21. The company has a market cap of $961.85 million, a PE ratio of -2.65, a price-to-earnings-growth ratio of 2.85 and a beta of 2.92. Novavax has a twelve month low of $3.81 and a twelve month high of $23.86.

Novavax (NASDAQ:NVAX) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.24. The business had revenue of $88.31 million for the quarter, compared to analyst estimates of $85.48 million. During the same period in the previous year, the firm posted ($1.44) earnings per share. As a group, research analysts anticipate that Novavax will post -1.46 EPS for the current fiscal year.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.